MedTrace Logo

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

NCT06439602 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 818

Last updated 2026-05-13

No results posted yet for this study

Summary

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Conditions

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Interventions

DRUG

AR882 50 mg

Solid Oral Capsule

DRUG

AR882 75 mg

Solid Oral Capsule

DRUG

Placebo

Matching Solid Oral Capsule Placebo

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • Robert Keenan, MD · Arthrosi Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-26
Primary Completion
2026-03-20
Completion
2026-04-10
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Hong Kong
  • New Zealand
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06439602 on ClinicalTrials.gov